Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR‐mutated lung cancer treated with the first‐/second‐generation tyrosine kinase inhibitors

Ähnliche Einträge

• Influence of TP53 mutation on efficacy and survival in advanced EGFR‐mutant non‐small cell lung cancer patients treated with third‐generation EGFR tyrosine kinase inhibitors
  von: Zhonghan Zhang, et al.
  Veröffentlicht: (2024)
• Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3‐tyrosine kinase domain mutations: Prognostic implications of NPM1 co‐mutation
  von: Sankalp Arora, et al.
  Veröffentlicht: (2025)
• Kinematic analysis of kinases and their oncogenic mutations – Kinases and their mutation kinematic analysis
  von: Xiyu Chen, et al.
  Veröffentlicht: (2024)
• EGFR amplification indicated poor prognosis in EGFR‐mutated lung cancer with leptomeningeal metastases
  von: Di Geng, et al.
  Veröffentlicht: (2024)
• Study of EGFR mutations in head and neck squamous cell carcinomas
  von: Gurpreet Kaur
  Veröffentlicht: (2021)